Comparing CagriSema and Semaglutide 2.4 mg alone for weight loss in adults with overweight or obesity, with or without type 2 diabetes

CagriSema, a combination of cagrilintide and semaglutide, may provide added weight-loss benefits beyond semaglutide 2.4 mg alone.

• CagriSema is designed to utilize complementary mechanisms for weight management.
• The efficacy and safety of CagriSema were compared to semaglutide 2.4 mg in adults with overweight or obesity.
• Outcomes were assessed in participants both with and without type 2 diabetes.
• Many patients on semaglutide 2.4 mg do not achieve significant weight-loss targets.

Simplified